查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
亚太地区癫痫市场预测至 2030 年 - 区域分析 - 按类型、给药途径、治疗类型、年龄层和配销通路
市场调查报告书
商品编码
1592587

亚太地区癫痫市场预测至 2030 年 - 区域分析 - 按类型、给药途径、治疗类型、年龄层和配销通路

Asia Pacific Epilepsy Market Forecast to 2030 - Regional Analysis - by Type, Route of Administration, Treatment Type, Age Group, and Distribution Channel
出版日期: | 出版商: The Insight Partners | 英文 146 Pages | 订单完成后即时交付

价格

2022年亚太地区癫痫市场价值为22.0092亿美元，预计到2030年将达到31.4344亿美元；预计2022年至2030年复合年增长率为4.6%。

各组织所进行的意识激增计画推动亚太地区癫痫市场发展

人们对癫痫及其症状以及早期诊断重要性的认识不断提高，导致寻求医疗救助的患者数量激增。癫痫基金会、癫痫协会、美国癫痫协会和佛罗里达州中部癫痫协会等组织在教育人们了解这种疾病方面发挥着至关重要的作用。这些组织的参与提高了诊断率，并扩大了需要癫痫治疗的患者群体。世界各地的组织开展了许多宣传活动，以提高人们对这种疾病和可用治疗的认识。 2023 年，在癫痫紫色日，印度海得拉巴的 Aster Prime 医院与克里希纳康德公园步行者协会合作举办了一场宣传活动。共有一百五十名参与者，包括步行者和瑜伽练习者参加了本次活动。此外，为了改善澳洲癫痫患者的生活质量，澳洲癫痫行动组织提供各种工具和服务，旨在提高认识、教育个人并为他们提供必要的技能。因此，此类措施和宣传活动导致癫痫诊断和治疗的增加，为市场提供了利润丰厚的成长机会。

亚太地区癫痫市场概况

我们根据中国、日本、印度、澳洲、韩国和亚太其他地区分析了亚太地区癫痫市场。根据世界卫生组织（WHO）报告，癫痫在发展中国家比已开发国家更为常见，盛行率分别为6.1%和5.0%。

亚太地区癫痫市场收入及 2030 年预测（百万美元）

亚太地区癫痫市场细分

亚太地区癫痫市场按类型、给药途径、治疗类型、年龄层、配销通路和国家分类。

依类型，亚太地区癫痫市场分为进行性肌阵挛癫痫、反射性癫痫、全身性癫痫等。 2022 年，全身性癫痫细分市场占最大市场。

就给药途径而言，亚太地区癫痫市场分为口服、肠胃外和其他。 2022 年，口腔细分市场占据最大的市场份额。

依治疗类型，亚太地区癫痫市场分为第一代药物、第二代药物和第三代药物。 2022年，第三代药物细分市场占据最大市场份额。

根据年龄组，亚太地区癫痫市场分为成人和儿童。 2022 年，成人细分市场将占据更大的市场份额。

从配销通路来看，亚太癫痫市场分为医院药局、零售药局等。 2022年，医院药局领域占据最大的市场份额。

依国家划分，亚太地区癫痫市场分为中国、日本、印度、澳洲、韩国和亚太其他地区。 2022年，中国在亚太地区癫痫市场份额中占据主导地位。

雅培实验室、辉瑞公司、卫材有限公司、UCB SA、LivaNova Plc、诺华公司、美敦力公司、葛兰素史克公司和 H. Lundbeck AS 是亚太地区癫痫市场的一些领导公司。

目录

第 1 章：简介

第 2 章：执行摘要

  • 主要见解
  • 市场吸引力

第 3 章：研究方法

  • 覆盖范围
  • 二次研究
  • 初步研究

第 4 章：亚太地区癫痫治疗方法的管道研究

  • 癫痫治疗方法的管道研究
    • 细胞和基因治疗方法
    • 胶囊细胞生物递送（ECB）系统
    • 癫痫基因治疗临床概述
      • 癫痫临床研究采用基因疗法
      • 癫痫病毒载体的管道研究
      • 癫痫非病毒载体的管道研究
      • 腺相关病毒 (AAV) 介导的神经调节胜肽 - 概述
      • 基因治疗方法的神经营养因子
      • 人类癫痫表型的钾通道
      • 酶诱导抗癫痫药

第 5 章：亚太地区癫痫市场 - 主要市场动态

  • 市场驱动因素
    • 癫痫盛行率上升
    • 增加癫痫疗法开发的投资
  • 市场限制
    • 产品召回
  • 市场机会
    • 组织所进行的意识计画激增
  • 未来趋势
    • 基因疗法作为有前景的治疗方法
  • 驱动因素和限制的影响：

第 6 章：癫痫市场 - 亚太地区分析

  • 亚太地区：癫痫市场

第 7 章：亚太地区癫痫市场分析 - 按类型

  • 概述
  • 进行性肌阵挛癫痫
  • 反射性癫痫
  • 全身性癫痫
  • 其他

第 8 章：亚太地区癫痫市场分析 - 按给药途径

  • 概述
  • 口服
  • 注射用
  • 其他的

第 9 章：亚太地区癫痫市场分析 - 按治疗类型

  • 概述
  • 第一代药物
  • 第二代药物
  • 第三代药物

第 10 章：亚太地区癫痫市场分析 - 按年龄组

  • 概述
  • 成人
  • 孩子们

第 11 章：亚太地区癫痫市场分析 - 按配销通路

  • 概述
  • 医院药房
  • 零售药局
  • 其他的

第 12 章：亚太地区癫痫市场 - 国家分析

    • 亚太地区
      • 中国
      • 日本
      • 印度
      • 澳洲
      • 韩国
      • 亚太地区其他地区

第 13 章：产业格局

  • 概述
  • 癫痫市场的成长策略
  • 有机成长策略
    • 概述
  • 无机成长策略
    • 概述

第 14 章：公司简介

  • Abbott Laboratories
  • Pfizer Inc
  • Eisai Co Ltd
  • UCB SA
  • LivaNova Plc
  • Novartis AG
  • Medtronic Plc
  • GSK Plc
  • H. Lundbeck AS

第 15 章：附录

Product Code: BMIRE00030724

The Asia Pacific epilepsy market was valued at US$ 2,200.92 million in 2022 and is expected to reach US$ 3,143.44 million by 2030; it is estimated to register a CAGR of 4.6% from 2022 to 2030.

Surge in Awareness Program Conducted by Organizations Boosts Asia Pacific Epilepsy Market

Growing awareness about epilepsy, its symptoms, and the importance of early diagnosis has led to a surge in patients seeking medical attention. Organizations such as the Epilepsy Foundation, Epilepsy Society, the American Epilepsy Society, and the Epilepsy Association of Central Florida play a crucial role in educating people about this disease. The involvement of these organizations has resulted in increased rates of diagnosis and a broader patient population requiring epilepsy treatment. Numerous awareness campaigns are conducted by organizations worldwide to spread awareness regarding the condition and available treatment. In 2023, on the Purple Day of Epilepsy, Aster Prime Hospitals in Hyderabad (India), in collaboration with the Walkers Association of Krishna Kant Park, held an awareness activity. One hundred fifty participants in total, including walkers and yoga practitioners, attended this session. Additionally, in order to improve the quality of life for Australians living with epilepsy, Epilepsy Action Australia offers a variety of tools and services aimed at raising awareness, educating, and equipping individuals with the necessary skills. Thus, such initiatives and awareness campaigns result in an increase in epilepsy diagnoses and treatments, offering lucrative growth opportunities to the market.

Asia Pacific Epilepsy Market Overview

The Asia Pacific epilepsy market is analyzed based on China, Japan, India, Australia, South Korea, and the Rest of Asia Pacific. According to the World Health Organization (WHO) report, epilepsy is more common in developing countries than in developed countries, accounting for a prevalence of 6.1% and 5.0%, respectively.

Asia Pacific Epilepsy Market Revenue and Forecast to 2030 (US$ Million)

Asia Pacific Epilepsy Market Segmentation

The Asia Pacific epilepsy market is categorized into type, route of administration, treatment type, age group, distribution channel, and country.

Based on type, the Asia Pacific epilepsy market is categorized into progressive myoclonic epilepsy, reflex epilepsy, generalized epilepsy, and other. The generalized epilepsy segment held the largest market share in 2022.

In terms of route of administration, the Asia Pacific epilepsy market is categorized into oral, parenteral, and others. The oral segment held the largest market share in 2022.

By treatment type, the Asia Pacific epilepsy market is segmented into first generation drugs, second generation drugs, and third generation drugs. The third generation drugs segment held the largest market share in 2022.

Based on age group, the Asia Pacific epilepsy market is bifurcated into adult and children. The adult segment held a larger market share in 2022.

In terms of distribution channel, the Asia Pacific epilepsy market is categorized into hospital pharmacies, retail pharmacies, and others. The hospital pharmacies segment held the largest market share in 2022.

By country, the Asia Pacific epilepsy market is segmented into China, Japan, India, Australia, South Korea, and the Rest of Asia Pacific. China dominated the Asia Pacific epilepsy market share in 2022.

Abbott Laboratories, Pfizer Inc, Eisai Co Ltd, UCB SA, LivaNova Plc, Novartis AG, Medtronic Plc, GSK Plc, and H. Lundbeck AS are some of the leading companies operating in the Asia Pacific epilepsy market.

Table Of Contents

1. Introduction

  • 1.1 The Insight Partners Research Report Guidance
  • 1.2 Market Segmentation

2. Executive Summary

  • 2.1 Key Insights
  • 2.2 Market Attractiveness

3. Research Methodology

  • 3.1 Coverage
  • 3.2 Secondary Research
  • 3.3 Primary Research

4. Asia Pacific Pipeline Studies for Epilepsy Therapy Approaches

  • 4.1 Pipeline Studies for Epilepsy Therapy Approaches
    • 4.1.1 Cell and Gene Therapy Approaches
    • 4.1.2 Encapsulated cell bio delivery (ECB) system
    • 4.1.3 Gene Therapy for Epilepsy Clinical Overview
      • 4.1.3.1 Genetic Therapies Adopted for Clinic Research of Epilepsy
        • 4.1.3.1.1 Gene Supplementation - Overview
        • 4.1.3.1.2 Gene Modulation - Overview
        • 4.1.3.1.3 Antisense Oligonucleotides and RNA Interference - Overview
        • 4.1.3.1.4 Neuropeptides - Overview
        • 4.1.3.1.5 Engineered Channels - Overview
        • 4.1.3.1.6 Endogenous Channels - Overview
      • 4.1.3.2 Pipeline Studies of Viral Vectors for Epilepsy
      • 4.1.3.3 Pipeline Studies of Non-Viral Vectors for Epilepsy
        • 4.1.3.3.1 Polymer-based Non-Viral Vectors for Epilepsy
        • 4.1.3.3.2 Lipid-based Non-Viral Vectors for Epilepsy
      • 4.1.3.4 Adeno-Associated Virus (AAV)-Mediated Neuromodulatory Peptides - Overview
      • 4.1.3.5 Neurotrophic Factors for Gene Therapy Approaches
      • 4.1.3.6 Potassium Channels For Human Epileptic Phenotypes
      • 4.1.3.7 Enzyme Inducing Antiepileptic Drugs

5. Asia Pacific Epilepsy Market - Key Market Dynamics

  • 5.1 Market Drivers
    • 5.1.1 Rising Prevalence of Epilepsy
    • 5.1.2 Increasing Investments in Development of Epilepsy Therapies
  • 5.2 Market Restraints
    • 5.2.1 Recall of Products
  • 5.3 Market Opportunities
    • 5.3.1 Surge in Awareness Programs Conducted by Organizations
  • 5.4 Future Trends
    • 5.4.1 Gene Therapy as Promising Treatment Approach
  • 5.5 Impact of Drivers and Restraints:

6. Epilepsy Market - Asia Pacific Analysis

  • 6.1 Asia Pacific: Epilepsy Market

7. Asia Pacific Epilepsy Market Analysis - by Type

  • 7.1 Overview
  • 7.2 Progressive Myoclonic Epilepsy
    • 7.2.1 Overview
    • 7.2.2 Progressive Myoclonic Epilepsy: Epilepsy Market - Revenue and Forecast to 2030 (US$ Million)
  • 7.3 Reflex Epilepsy
    • 7.3.1 Overview
    • 7.3.2 Reflex Epilepsy: Epilepsy Market - Revenue and Forecast to 2030 (US$ Million)
  • 7.4 Generalized Epilepsy
    • 7.4.1 Overview
    • 7.4.2 Generalized Epilepsy: Epilepsy Market - Revenue and Forecast to 2030 (US$ Million)
  • 7.5 Other
    • 7.5.1 Overview
    • 7.5.2 Other: Epilepsy Market - Revenue and Forecast to 2030 (US$ Million)

8. Asia Pacific Epilepsy Market Analysis - by Route of Administration

  • 8.1 Overview
  • 8.2 Oral
    • 8.2.1 Overview
    • 8.2.2 Oral: Epilepsy Market - Revenue and Forecast to 2030 (US$ Million)
  • 8.3 Parenteral
    • 8.3.1 Overview
    • 8.3.2 Parenteral: Epilepsy Market - Revenue and Forecast to 2030 (US$ Million)
  • 8.4 Others
    • 8.4.1 Overview
    • 8.4.2 Others: Epilepsy Market - Revenue and Forecast to 2030 (US$ Million)

9. Asia Pacific Epilepsy Market Analysis - by Treatment Type

  • 9.1 Overview
  • 9.2 First Generation Drugs
    • 9.2.1 Overview
    • 9.2.2 First Generation Drugs: Epilepsy Market - Revenue and Forecast to 2030 (US$ Million)
  • 9.3 Second Generation Drugs
    • 9.3.1 Overview
    • 9.3.2 Second Generation Drugs: Epilepsy Market - Revenue and Forecast to 2030 (US$ Million)
  • 9.4 Third Generation Drugs
    • 9.4.1 Overview
    • 9.4.2 Third Generation Drugs: Epilepsy Market - Revenue and Forecast to 2030 (US$ Million)

10. Asia Pacific Epilepsy Market Analysis - by Age Group

  • 10.1 Overview
  • 10.2 Adult
    • 10.2.1 Overview
    • 10.2.2 Adult: Epilepsy Market - Revenue and Forecast to 2030 (US$ Million)
  • 10.3 Children
    • 10.3.1 Overview
    • 10.3.2 Children: Epilepsy Market - Revenue and Forecast to 2030 (US$ Million)

11. Asia Pacific Epilepsy Market Analysis - by Distribution Channel

  • 11.1 Overview
  • 11.2 Hospital Pharmacies
    • 11.2.1 Overview
    • 11.2.2 Hospital Pharmacies: Epilepsy Market - Revenue and Forecast to 2030 (US$ Million)
  • 11.3 Retail Pharmacies
    • 11.3.1 Overview
    • 11.3.2 Retail Pharmacies: Epilepsy Market - Revenue and Forecast to 2030 (US$ Million)
  • 11.4 Others
    • 11.4.1 Overview
    • 11.4.2 Others: Epilepsy Market - Revenue and Forecast to 2030 (US$ Million)

12. Asia Pacific Epilepsy Market - Country Analysis

  • 12.1 Asia Pacific Epilepsy Market Overview
    • 12.1.1 Asia Pacific: Epilepsy Market Breakdown, by Key Country, 2022 and 2030 (%)
      • 12.1.1.1 China: Epilepsy Market Overview
      • 12.1.1.2 China: Epilepsy Market - Revenue and Forecast to 2030 (US$ Million)
        • 12.1.1.2.1 China: Epilepsy Market Breakdown, by Type
        • 12.1.1.2.2 China: Epilepsy Market Breakdown, by Route of Administration
        • 12.1.1.2.3 China: Epilepsy Market Breakdown, by Treatment Type
        • 12.1.1.2.4 China: Epilepsy Market Breakdown, by Age Group
        • 12.1.1.2.5 China: Epilepsy Market Breakdown, by Distribution Channel
      • 12.1.1.3 Japan: Epilepsy Market Overview
      • 12.1.1.4 Japan: Epilepsy Market - Revenue and Forecast to 2030 (US$ Million)
        • 12.1.1.4.1 Japan: Epilepsy Market Breakdown, by Type
        • 12.1.1.4.2 Japan: Epilepsy Market Breakdown, by Route of Administration
        • 12.1.1.4.3 Japan: Epilepsy Market Breakdown, by Treatment Type
        • 12.1.1.4.4 Japan: Epilepsy Market Breakdown, by Age Group
        • 12.1.1.4.5 Japan: Epilepsy Market Breakdown, by Distribution Channel
      • 12.1.1.5 India: Epilepsy Market Overview
      • 12.1.1.6 India: Epilepsy Market - Revenue and Forecast to 2030 (US$ Million)
        • 12.1.1.6.1 India: Epilepsy Market Breakdown, by Type
        • 12.1.1.6.2 India: Epilepsy Market Breakdown, by Route of Administration
        • 12.1.1.6.3 India: Epilepsy Market Breakdown, by Treatment Type
        • 12.1.1.6.4 India: Epilepsy Market Breakdown, by Age Group
        • 12.1.1.6.5 India: Epilepsy Market Breakdown, by Distribution Channel
      • 12.1.1.7 Australia: Epilepsy Market Overview
      • 12.1.1.8 Australia: Epilepsy Market - Revenue and Forecast to 2030 (US$ Million)
        • 12.1.1.8.1 Australia: Epilepsy Market Breakdown, by Type
        • 12.1.1.8.2 Australia: Epilepsy Market Breakdown, by Route of Administration
        • 12.1.1.8.3 Australia: Epilepsy Market Breakdown, by Treatment Type
        • 12.1.1.8.4 Australia: Epilepsy Market Breakdown, by Age Group
        • 12.1.1.8.5 Australia: Epilepsy Market Breakdown, by Distribution Channel
      • 12.1.1.9 South Korea: Epilepsy Market Overview
      • 12.1.1.10 South Korea: Epilepsy Market - Revenue and Forecast to 2030 (US$ Million)
        • 12.1.1.10.1 South Korea: Epilepsy Market Breakdown, by Type
        • 12.1.1.10.2 South Korea: Epilepsy Market Breakdown, by Route of Administration
        • 12.1.1.10.3 South Korea: Epilepsy Market Breakdown, by Treatment Type
        • 12.1.1.10.4 South Korea: Epilepsy Market Breakdown, by Age Group
        • 12.1.1.10.5 South Korea: Epilepsy Market Breakdown, by Distribution Channel
      • 12.1.1.11 Rest of Asia Pacific: Epilepsy Market Overview
      • 12.1.1.12 Rest of Asia Pacific: Epilepsy Market - Revenue and Forecast to 2030 (US$ Million)
        • 12.1.1.12.1 Rest of Asia Pacific: Epilepsy Market Breakdown, by Type
        • 12.1.1.12.2 Rest of Asia Pacific: Epilepsy Market Breakdown, by Route of Administration
        • 12.1.1.12.3 Rest of Asia Pacific: Epilepsy Market Breakdown, by Treatment Type
        • 12.1.1.12.4 Rest of Asia Pacific: Epilepsy Market Breakdown, by Age Group
        • 12.1.1.12.5 Rest of Asia Pacific: Epilepsy Market Breakdown, by Distribution Channel

13. Industry Landscape

  • 13.1 Overview
  • 13.2 Growth Strategies in Epilepsy Market
  • 13.3 Organic Growth Strategies
    • 13.3.1 Overview
  • 13.4 Inorganic Growth Strategies
    • 13.4.1 Overview

14. Company Profiles

  • 14.1 Abbott Laboratories
    • 14.1.1 Key Facts
    • 14.1.2 Business Description
    • 14.1.3 Products and Services
    • 14.1.4 Financial Overview
    • 14.1.5 SWOT Analysis
    • 14.1.6 Key Developments
  • 14.2 Pfizer Inc
    • 14.2.1 Key Facts
    • 14.2.2 Business Description
    • 14.2.3 Products and Services
    • 14.2.4 Financial Overview
    • 14.2.5 SWOT Analysis
    • 14.2.6 Key Developments
  • 14.3 Eisai Co Ltd
    • 14.3.1 Key Facts
    • 14.3.2 Business Description
    • 14.3.3 Products and Services
    • 14.3.4 Financial Overview
    • 14.3.5 SWOT Analysis
    • 14.3.6 Key Developments
  • 14.4 UCB SA
    • 14.4.1 Key Facts
    • 14.4.2 Business Description
    • 14.4.3 Products and Services
    • 14.4.4 Financial Overview
    • 14.4.5 SWOT Analysis
    • 14.4.6 Key Developments
  • 14.5 LivaNova Plc
    • 14.5.1 Key Facts
    • 14.5.2 Business Description
    • 14.5.3 Products and Services
    • 14.5.4 Financial Overview
    • 14.5.5 SWOT Analysis
    • 14.5.6 Key Developments
  • 14.6 Novartis AG
    • 14.6.1 Key Facts
    • 14.6.2 Business Description
    • 14.6.3 Products and Services
    • 14.6.4 Financial Overview
    • 14.6.5 SWOT Analysis
    • 14.6.6 Key Developments
  • 14.7 Medtronic Plc
    • 14.7.1 Key Facts
    • 14.7.2 Business Description
    • 14.7.3 Products and Services
    • 14.7.4 Financial Overview
    • 14.7.5 SWOT Analysis
    • 14.7.6 Key Developments
  • 14.8 GSK Plc
    • 14.8.1 Key Facts
    • 14.8.2 Business Description
    • 14.8.3 Products and Services
    • 14.8.4 Financial Overview
    • 14.8.5 SWOT Analysis
    • 14.8.6 Key Developments
  • 14.9 H. Lundbeck AS
    • 14.9.1 Key Facts
    • 14.9.2 Business Description
    • 14.9.3 Products and Services
    • 14.9.4 Financial Overview
    • 14.9.5 SWOT Analysis
    • 14.9.6 Key Developments

15. Appendix

  • 15.1 About The Insight Partners

List Of Tables

  • Table 1. Asia Pacific Epilepsy Market Segmentation
  • Table 2. Cell Therapy Approach - An Overview
  • Table 3. Gene Therapy Approach - An Overview
  • Table 4. Encapsulated cell bio delivery (ECB) system Cell and Gene Therapy Approach - An Overview
  • Table 5. Preclinically Tested Genetic Therapies for Epilepsy
  • Table 6. Clinical Trials for Epilepsy Gene Therapy: Overview
  • Table 7. Viral Vectors Comparison with respect to Various Parameters
  • Table 8. Subfamilies of Human K+ Channels Involved in Epilepsies
  • Table 9. Enzyme-Inducing Antiepileptic Drugs
  • Table 10. Enzyme-Inducing Antiepileptic Drugs & Drug Targets Types Overview
  • Table 11. China: Epilepsy Market - Revenue and Forecast to 2030(US$ Million) - by Type
  • Table 12. China: Epilepsy Market - Revenue and Forecast to 2030(US$ Million) - by Route of Administration
  • Table 13. China: Epilepsy Market - Revenue and Forecast to 2030(US$ Million) - by Treatment Type
  • Table 14. China: Epilepsy Market - Revenue and Forecast to 2030(US$ Million) - by Age Group
  • Table 15. China: Epilepsy Market - Revenue and Forecast to 2030(US$ Million) - by Distribution Channel
  • Table 16. Japan: Epilepsy Market - Revenue and Forecast to 2030(US$ Million) - by Type
  • Table 17. Japan: Epilepsy Market - Revenue and Forecast to 2030(US$ Million) - by Route of Administration
  • Table 18. Japan: Epilepsy Market - Revenue and Forecast to 2030(US$ Million) - by Treatment Type
  • Table 19. Japan: Epilepsy Market - Revenue and Forecast to 2030(US$ Million) - by Age Group
  • Table 20. Japan: Epilepsy Market - Revenue and Forecast to 2030(US$ Million) - by Distribution Channel
  • Table 21. India: Epilepsy Market - Revenue and Forecast to 2030(US$ Million) - by Type
  • Table 22. India: Epilepsy Market - Revenue and Forecast to 2030(US$ Million) - by Route of Administration
  • Table 23. India: Epilepsy Market - Revenue and Forecast to 2030(US$ Million) - by Treatment Type
  • Table 24. India: Epilepsy Market - Revenue and Forecast to 2030(US$ Million) - by Age Group
  • Table 25. India: Epilepsy Market - Revenue and Forecast to 2030(US$ Million) - by Distribution Channel
  • Table 26. Australia: Epilepsy Market - Revenue and Forecast to 2030(US$ Million) - by Type
  • Table 27. Australia: Epilepsy Market - Revenue and Forecast to 2030(US$ Million) - by Route of Administration
  • Table 28. Australia: Epilepsy Market - Revenue and Forecast to 2030(US$ Million) - by Treatment Type
  • Table 29. Australia: Epilepsy Market - Revenue and Forecast to 2030(US$ Million) - by Age Group
  • Table 30. Australia: Epilepsy Market - Revenue and Forecast to 2030(US$ Million) - by Distribution Channel
  • Table 31. South Korea: Epilepsy Market - Revenue and Forecast to 2030(US$ Million) - by Type
  • Table 32. South Korea: Epilepsy Market - Revenue and Forecast to 2030(US$ Million) - by Route of Administration
  • Table 33. South Korea: Epilepsy Market - Revenue and Forecast to 2030(US$ Million) - by Treatment Type
  • Table 34. South Korea: Epilepsy Market - Revenue and Forecast to 2030(US$ Million) - by Age Group
  • Table 35. South Korea: Epilepsy Market - Revenue and Forecast to 2030(US$ Million) - by Distribution Channel
  • Table 36. Rest of Asia Pacific: Epilepsy Market - Revenue and Forecast to 2030(US$ Million) - by Type
  • Table 37. Rest of Asia Pacific: Epilepsy Market - Revenue and Forecast to 2030(US$ Million) - by Route of Administration
  • Table 38. Rest of Asia Pacific: Epilepsy Market - Revenue and Forecast to 2030(US$ Million) - by Treatment Type
  • Table 39. Rest of Asia Pacific: Epilepsy Market - Revenue and Forecast to 2030(US$ Million) - by Age Group
  • Table 40. Rest of Asia Pacific: Epilepsy Market - Revenue and Forecast to 2030(US$ Million) - by Distribution Channel
  • Table 41. Recent Organic Growth Strategies in Epilepsy Market
  • Table 42. Recent Inorganic Growth Strategies in the Epilepsy Market

List Of Figures

  • Figure 1. Asia Pacific Epilepsy Market Segmentation, by Country
  • Figure 2. Epilepsy Market - Key Market Dynamics
  • Figure 3. Impact Analysis of Drivers and Restraints
  • Figure 4. Epilepsy Market Revenue (US$ Million), 2020-2030
  • Figure 5. Epilepsy Market Share (%) - by Type (2022 and 2030)
  • Figure 6. Progressive Myoclonic Epilepsy: Epilepsy Market - Revenue and Forecast to 2030 (US$ Million)
  • Figure 7. Reflex Epilepsy: Epilepsy Market - Revenue and Forecast to 2030 (US$ Million)
  • Figure 8. Generalized Epilepsy: Epilepsy Market - Revenue and Forecast to 2030 (US$ Million)
  • Figure 9. Other: Epilepsy Market - Revenue and Forecast to 2030 (US$ Million)
  • Figure 10. Epilepsy Market Share (%) - by Route of Administration (2022 and 2030)
  • Figure 11. Oral: Epilepsy Market - Revenue and Forecast to 2030 (US$ Million)
  • Figure 12. Parenteral: Epilepsy Market - Revenue and Forecast to 2030 (US$ Million)
  • Figure 13. Others: Epilepsy Market - Revenue and Forecast to 2030 (US$ Million)
  • Figure 14. Epilepsy Market Share (%) - by Treatment Type (2022 and 2030)
  • Figure 15. First Generation Drugs: Epilepsy Market - Revenue and Forecast to 2030 (US$ Million)
  • Figure 16. Second Generation Drugs: Epilepsy Market - Revenue and Forecast to 2030 (US$ Million)
  • Figure 17. Third Generation Drugs: Epilepsy Market - Revenue and Forecast to 2030 (US$ Million)
  • Figure 18. Epilepsy Market Share (%) - by Age Group (2022 and 2030)
  • Figure 19. Adult: Epilepsy Market - Revenue and Forecast to 2030 (US$ Million)
  • Figure 20. Children: Epilepsy Market - Revenue and Forecast to 2030 (US$ Million)
  • Figure 21. Epilepsy Market Share (%) - by Distribution Channel (2022 and 2030)
  • Figure 22. Hospital Pharmacies: Epilepsy Market - Revenue and Forecast to 2030 (US$ Million)
  • Figure 23. Retail Pharmacies: Epilepsy Market - Revenue and Forecast to 2030 (US$ Million)
  • Figure 24. Others: Epilepsy Market - Revenue and Forecast to 2030 (US$ Million)
  • Figure 25. Asia Pacific: Epilepsy Market, by Key Country - Revenue (2022) (US$ Million)
  • Figure 26. Asia Pacific: Epilepsy Market Breakdown, by Key Countries, 2022 and 2030 (%)
  • Figure 27. China: Epilepsy Market - Revenue and Forecast to 2030(US$ Million)
  • Figure 28. Japan: Epilepsy Market - Revenue and Forecast to 2030(US$ Million)
  • Figure 29. India: Epilepsy Market - Revenue and Forecast to 2030(US$ Million)
  • Figure 30. Australia: Epilepsy Market - Revenue and Forecast to 2030(US$ Million)
  • Figure 31. South Korea: Epilepsy Market - Revenue and Forecast to 2030(US$ Million)
  • Figure 32. Rest of Asia Pacific: Epilepsy Market - Revenue and Forecast to 2030(US$ Million)
  • Figure 33. Growth Strategies in Epilepsy Market